Claris Bio Receives Investment

Claris Bio, a clinical-stage biotechnology company focused on corneal disease therapies, has received investment. The $57 million investment was led by Novo Holdings, RA Capital, Mass General Brigham Ventures and Janus Henderson Investors. The company stated that it will use the new investment to expand its operational area and intensify its R&D efforts. In addition to Mr Atwell, Claris' leadership team includes CMO Susan Orr and OD and Chief Operating Officer Henry Rath.

Also Read: Cleva Receives $1.5 Million Pre-Seed Investment from Y Combinator

Claris Bio

It is developing recombinant human variant hepatocyte growth factor (dHGF) to accelerate and improve the quality of corneal healing in patients with corneal eye disease. Its lead programme CSB-001 Ophthalmic Solution 0.1 percent (oremepermin-α) brings to eyes with neurotrophic keratopathy (NK) a topical ocular biological solution of dHGF, a molecule with the potential to restore structural and functional corneal integrity. Oremepermin-α is epitheliotropic, neurotrophic, anti-inflammatory and anti-fibrotic. It suggests that it may be an effective and safe option to treat many current unmet needs, also in corneal diseases. Claris expects to complete enrolment in the late-stage multicentre, randomised, double-masked, double-masked, vehicle-controlled, parallel-group study, with data readout to be completed in the first half of 2024.